Chronic paranoid psychosis after misuse of MDMA ("ecstasy")
نویسندگان
چکیده
منابع مشابه
Ecstasy (MDMA) dependence.
Methylenedioxymethamphetamine (MDMA) is generally described as non-addictive. However, this report describes three cases in which criteria for dependence were met. A wider understanding that MDMA can be addictive in rare cases is important as very heavy use may cause lasting neuronal changes. This risk could be reduced with effective identification and treatment of dependent persons. In one cas...
متن کاملEcstasy: 3,4-methylenedioxymethamphetamine (MDMA).
The crystal structure of 3,4-methylenedioxymethamphetamine [systematic name: N-methyl-1-[3,4-(methylenedioxy) phenyl]-2-aminopropane] hydrochloride, C11H15NO2.HCl, also known as 'ecstasy' or MDMA, has been determined by X-ray diffraction.
متن کاملEffect of pentoxifylline on histomorphological changes of kidney after Ecstasy (MDMA) administration in male wistar rat.
Methylenedioxymethamphetamine (MDMA),the Ecstasy brand, leads to cell death in many tissues such askidney because of its oxidative properties. The present study aimed to investigate the possible effects ofpentoxifylline as a vasodilators on ecstasy induced renal damage. This experimental study was carried out infour groups of six male wistar rats weighing 250-300 g (n=24). The control group was...
متن کاملChronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.
This review of chronic tolerance to MDMA (3,4-methylenedioxymetamphetamine) covers the empirical data on dosage escalation, reduced subjective efficacy and bingeing in recreational Ecstasy users. Novice users generally take a single Ecstasy tablet, regular users typically take 2-3 tablets, whereas the most experienced users may take 10-25 tablets in a single session. Reduced subjective efficacy...
متن کامل( " ecstasy " ) ingestion . A pure amnestic syndrome after MDMA
Our patient, a thirty eight year old woman, had had relapsing-remitting multiple sclerosis since the age of 17. In September 1995 interferon-fl lb (B-IFN, Betaferon, Schering) was introduced. After a training session the patient injected 8 million IU on alternate days. Injection sites were the thighs and the abdomen. The patient was seen 2, 4, 8, and 12 weeks after the beginning of the therapy....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1991
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.302.6778.697